Biogen cuts price of controversial Aduhelm in half
Dec 21, 2021
The drug shows promise in clearing the brain plaques believed to play a role in Alzheimer’s disease.
Medicare mulls coverage for controversial drug for Alzheimer’s disease
Jul 13, 2021
CMS says a final decision on coverage is not likely until next spring.
Medicare will cover new class of Alzheimer’s drugs if fully approved by FDA, with limits
Jun 02, 2023
Drug makers also will have to gather and keep data in a registry showing how the drugs are working in the real world.
Congressional report slams FDA, drugmaker over approval of Alzheimer’s drug Aduhelm
Dec 29, 2022
The controversy over aducanumab (Aduhelm) stretches back to its June 2021 approval by the US Food and Drug Administration.
Medicare monthly premiums to drop for seniors
Sep 28, 2022
The fee cuts come at the same time as seniors receive a Social Security cost-of-living increase for 2023 of up to 9 or 10%.
Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.
Medicare may rethink premium hike for pricey Alzheimer’s drug
Jan 10, 2022
The announcement comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to $28,000 a year.
Biden pledges to lower prescription drug prices for Americans
Dec 07, 2021
But the biggest policy change — letting Medicare negotiate prices for prescription drugs — will not start to lower costs until 2025.